An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times
Top Cited Papers
Open Access
- 27 April 2021
- Vol. 9 (5), 433
- https://doi.org/10.3390/vaccines9050433
Abstract
Since the worldwide COVID-19 pandemic was declared a year ago, the search for vaccines has become the top priority in order to restore normalcy after 2.5 million deaths worldwide, overloaded sanitary systems, and a huge economic burden. Vaccine development has represented a step towards the desired herd immunity in a short period of time, owing to a high level of investment, the focus of researchers, and the urge for the authorization of the faster administration of vaccines. Nevertheless, this objective may only be achieved by pursuing effective strategies and policies in various countries worldwide. In the present review, some aspects involved in accomplishing a successful vaccination program are addressed, in addition to the importance of vaccination in a pandemic in the face of unwillingness, conspiracy theories, or a lack of information among the public. Moreover, we provide some updated points related to the landscape of the clinical development of vaccine candidates, specifically, the top five vaccines that are already being assessed in Phase IV clinical trials (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S, and CoronaVac).Keywords
Funding Information
- Instituto de Salud Carlos III (PI18/00912)
- Consejería de Educación e Investigación (B2017/BMD3804)
This publication has 165 references indexed in Scilit:
- Animal models for highly pathogenic emerging virusesCurrent Opinion in Virology, 2013
- Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infectionNature Biotechnology, 2012
- A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal diseaseNature Medicine, 2012
- Developing mRNA-vaccine technologiesRNA Biology, 2012
- Heterologous prime–boost vaccinationCurrent Opinion in Immunology, 2009
- Duration of Antibody Responses after Severe Acute Respiratory SyndromeEmerging Infectious Diseases, 2007
- Chimpanzee-origin adenovirus vectors as vaccine carriersGene Therapy, 2005
- Adenoviruses as vaccine vectorsMolecular Therapy, 2004
- A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong KongThe New England Journal of Medicine, 2003
- Direct Gene Transfer into Mouse Muscle in VivoScience, 1990